BioXcel Therapeutics, Inc.
General ticker "BTAI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $35.4M (TTM average)
BioXcel Therapeutics, Inc. follows the US Stock Market performance with the rate: 1.5%.
Estimated limits based on current volatility of 6.9%: low 1.06$, high 1.22$
Factors to consider:
- Earnings expected soon, date: 2026-05-11 bmo
- Total employees count: 74 as of 2023
- Top business risk factors: Operational and conduct risks, Transition to commercial activities with unforeseen expenses, Potential disputes with bioxcel LLC, Third-party risks, Labor/talent shortage/retention
- Current price 14.8% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.41$, 4.99$]
- 2026-12-31 to 2027-12-31 estimated range: [0.96$, 3.55$]
Financial Metrics affecting the BTAI estimates:
- Positive: with PPE of -0.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -279.42 <= 0.07
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
Short-term BTAI quotes
Long-term BTAI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.38MM | $2.27MM | $0.64MM |
| Operating Expenses | $173.16MM | $69.51MM | $50.35MM |
| Operating Income | $-171.78MM | $-67.25MM | $-49.70MM |
| Non-Operating Income | $-7.27MM | $7.65MM | $-20.19MM |
| Interest Expense | $13.31MM | $15.13MM | $16.98MM |
| R&D Expense | $84.33MM | $30.43MM | $30.25MM |
| Income(Loss) | $-179.05MM | $-59.60MM | $-69.90MM |
| Profit(Loss)* | $-179.05MM | $-59.60MM | $-69.90MM |
| Stockholders Equity | $-56.51MM | $-93.10MM | $-95.46MM |
| Inventory | $1.99MM | $0.68MM | $0.72MM |
| Assets | $73.70MM | $38.34MM | $44.92MM |
| Operating Cash Flow | $-155.01MM | $-72.03MM | $-57.62MM |
| Capital expenditure | $0.02MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.02MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $26.52MM | $36.66MM | $56.52MM |
| Earnings Per Share** | $-98.35 | $-23.51 | $-5.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.